Skip to main content

Endophthalmitis: Gram Positive Ethiological Agents and Susceptibility to Glycopeptides

Buy Article:

$55.00 plus tax (Refund Policy)

Endophthalmitis is a serious sight-threatening condition, with a postoperative incidence of 0.13 -0.7%. This study aimed to investigate the spectrum of Gram-positive bacteria causing culture-proven endophthalmitis and their susceptibility to teicoplanin and vancomycin. At this purpose, minimum inhibitory concentrations of teicoplanin and vancomycin of Gram-positive bacteria isolated in the period 2001-2007 from vitreous cultures were determined.

Staphylococcus epidermidis was the most common organisms identified (31,8 %), followed by Staphylococcus aureus, Peptococcus spp. e Bacillus spp. All bacteria were susceptible to teicoplanin and vancomycin. The two drugs showed a comparable activity against staphylococci and bacilli, while teicoplanin was more potent against streptococci and anaerobes.

In conclusion, teicoplanin showed a spectrum of activity similar or even better that of vancomycin against the most common ethiological agents of postoperative endophthalmitis.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Endophthalmitis; Gram-positive bacteria; teicoplanin; vancomycin

Document Type: Research Article

Publication date: 2008-09-01

More about this publication?
  • Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more